Your browser doesn't support javascript.
loading
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.
Ahn, Jae-Sook; Kim, TaeHyung; Jung, Sung-Hoon; Ahn, Seo-Yeon; Jung, Seung-Yeon; Song, Ga-Young; Kim, Mihee; Yang, Deok-Hwan; Lee, Je-Jung; Choi, SeungHyun; Lee, Ja-Yeon; Park, Seong-Kyu; Moon, Joon Ho; Lee, Hui Young; Kim, Kyoung Ha; Cai, Yu; Yi, Seong Yoon; Novitzky-Basso, Igor; Zhang, Zhaolei; Kim, Hyeoung-Joon; Kim, Dennis Dong Hwan.
Afiliación
  • Ahn JS; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University, Gwangju, Republic of Korea.
  • Kim T; Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
  • Jung SH; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada.
  • Ahn SY; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada.
  • Jung SY; Department of Computer Science, University of Toronto, Toronto, ON, Canada.
  • Song GY; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University, Gwangju, Republic of Korea.
  • Kim M; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University, Gwangju, Republic of Korea.
  • Yang DH; Department of Hematology-Oncology, St Carollo Hospital, Jeollanam-do, Republic of Korea.
  • Lee JJ; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University, Gwangju, Republic of Korea.
  • Choi S; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University, Gwangju, Republic of Korea.
  • Lee JY; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University, Gwangju, Republic of Korea.
  • Park SK; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University, Gwangju, Republic of Korea.
  • Moon JH; Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
  • Lee HY; Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
  • Kim KH; Department of Hematology-Oncology, Soon Chun Hyang University Hospital, Bucheon, Republic of Korea.
  • Cai Y; Department of Hematology-Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Yi SY; Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, South Korea.
  • Novitzky-Basso I; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Zhang Z; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Kim HJ; Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Korea.
  • Kim DDH; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Bone Marrow Transplant ; 56(5): 1159-1170, 2021 05.
Article en En | MEDLINE | ID: mdl-33279940
In patients with acute myeloid leukemia (AML) consolidation treatment options are between allogeneic hematopoietic stem cell transplantation (HCT) and chemotherapy, based on disease risk at the time of initial presentation and age. Measurable residual disease (MRD) following induction chemotherapy could be incorporated as a useful parameter for treatment decisions. The present study evaluated treatment outcomes according to the next-generation sequencing (NGS)-based MRD status and the type of consolidation therapy in patients with normal karyotype (NK)-AML. By sequencing 278 paired samples collected at diagnosis and first remission (CR1), we identified 361 mutations in 124 patients at diagnosis and tracked these at CR1. After excluding mutations associated with age-related clonal hematopoiesis, 82 mutations in 50 of the 124 patients (40.3%) were detected at CR1. Survival benefit was observed in favor of allogeneic HCT over chemotherapy consolidation in the MRDpos subgroup with respect to overall survival (HR 0.294, p = 0.003), relapse-free survival (HR 0.376, p = 0.015) and cumulative incidence of relapse (HR 0.279, p = 0.004) in multivariate analysis, but not in the MRDneg subgroup. In summary, these data support allogeneic HCT in NK-AML patients with detectable MRD by NGS in CR1. Randomized clinical trials will be required to confirm this observation.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido